Orlando-based AdventHealth Cancer Institute has initiated a pioneering Phase II bladder cancer vaccine trial utilizing patient-specific mRNA vaccines.
Trial participants will receive pembrolizumab alongside a personalized immunotherapy injection tailored to the unique proteins in each patient's tumors. The treatment regimen includes infusions every six weeks for one year, followed by a vaccine injection every three weeks for a total of nine doses.
"This vaccine represents the pinnacle of precision medicine," stated Guru Sonpavde, MD, medical director of genitourinary oncology at AdventHealth Cancer Institute and a member of the trial’s global steering committee. He emphasized the potential of this approach to significantly improve patient outcomes by targeting the specific characteristics of each individual's cancer.
Click here to read the original news story.